GmbH announced today that it expects to launch in Europe in Q4 2012 a
next-generation Sirolimus-eluting coronary stent system—PROLIMUS
Biograde—which is designed to optimize long-term patient results.
Unlike many state-of-the-art DES that are currently being marketed, PROLIMUS
Biograde provides multiple pro-healing product features to promote
The thin-stent strut design of PROLIMUS Biograde, just 71
microns, minimizes stent-metal-volume, and thus foreign-body effects,
while providing uniform stent coverage through its strut architecture.
In addition, the PROLIMUS Biograde stent architecture
incorporates a diameter-depending 6-8-10 intermediate and closed-cell
stent design intended to cover all vessel diameters with the same ratio.
The goal of such design is to ensure a homogenous drug elution into the
arterial tissue of the stented lesion segment.
Furthermore, Cardionovum´s new DES is designed to protect allergic
patients against emission of metal ions. PROLIMUS Biograde is
coated with Titanium, which is highly biocompatible and functions as a
barrier against "metal-ion-bleeding" that prevents any stent-associated
hypersensitivity reaction. Especially high-risk patients such as
diabetics will benefit from this "following nature" stent philosophy of
Cardionovum. Most coronary stent systems now available do not combine
all of these clinically advantageous features, which contribute to lower